Descrizione del progetto
Prevedere l’evoluzione dell’infiammazione in malattia
L’infiammazione cronica è responsabile di numerose malattie, poiché arreca silenziosamente danni agli organi. Gioverebbe molto individuare biomarcatori in grado di predire l’infiammazione prima che si manifestino i sintomi e di fornire la stratificazione del rischio all’insorgenza della malattia. Per conseguire tale obiettivo, il progetto IMMEDIATE, finanziato dall’UE, si propone di individuare biomarcatori clinici e basati sull’omica per creare un punteggio relativo al rischio di progressione/resilienza alla malattia. Il lavoro verterà sul ruolo dei metaboliti del microbiota intestinale nella funzione del sistema immunitario e nell’infiammazione. Inoltre, il gruppo di ricerca analizzerà il risultato sulla salute e sul benessere derivante dalla modulazione del microbiota intestinale tramite prebiotici. I risultati getteranno le basi per uno stile di vita più sano.
Obiettivo
IMMEDIATE aims to investigate and explore the diet-microbiome-immunometabolism-axis as a sensor for health-to-disease transition and evaluate strategies to maintain an individual’s well-being. Chronic inflammation is the major root of most diseases. Understanding of this process preceding organ dysfunction or damage and identification of biomarkers in the pre-symptomatic stage and risk but also resilience factors of health-to-disease transition will enable targeted and personalized interventions to prevent irreversible organ damage. Metabolites of gut microbiota are key messengers between diet, microbiota and host, maintaining the balance of pro- and anti-inflammation. Our study takes advantage of cutting-edge omics technologies available within the IMMEDIATE consortium in conjunction with available clinical data and biospecimens from ongoing observational studies, enrolling “healthy” subjects and individuals in the pre-disease stage but with largely distinct environmental and dietary modulators, including a cohort of kidney transplant recipients in whom renal function has been “reset to baseline”. The identification of clinical and omics-derived biomarkers will – by employing AI algorithms - yield a personalized risk / resilience score of chronic inflammation and thus a better prediction of an individual’s risk of transition towards disease. A proof-of-concept intervention study with the anti-inflammatory microbe Akkermansia muciniphila will be conducted to test whether deflections of the microbiome-metabolite-immune axis can be reverted on the biomarker level but also with respect to clinical outcomes and overall well-being. Mobile apps developed by the IMMEDIATE consortium in collaboration with patient organizations tracking numerous lifestyle-related measures and providing guidance and feedback on these aspects will empower individuals to adopt and integrate these knowledge-based health interventions into their own lives, hereby self-managing their own health.
Campo scientifico
Parole chiave
Programma(i)
Argomento(i)
Meccanismo di finanziamento
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinatore
10117 Berlin
Germania